The journey to becoming the 200th participant for the TROG 18.01 NINJA Radiation Therapy Trial has been a remarkably quick...
Read more
Menu
Trans-Tasman Radiation Oncology Group is one of the largest cancer clinical trials groups in Australia and New Zealand.
Over three decades, TROG Cancer Research has facilitated more than 100 clinical trials that have helped improve the quality of life and treatment options for almost 15,000 volunteer cancer patients.
During that time, the prognosis of cancer patients has improved considerably. In the 1980s the cancer survival rate was less than 50 per cent. Today, for some cancers, the survival rate is as high as 90 per cent.
TROG Cancer Research is focused on radiation treatment, for the many types of cancers it can treat.
Our upcoming, current, and past clinical trials have investigated the effectiveness of radiation therapy in treating the following groups of cancers. Our members have also investigated the impact of radiation therapy on symptom management and palliative care.
View the successful TROG trial results and outcomes of all bladder, kidney and prostate cancers trials here.
Discover our research within bone cancers and the treatments and trials our team have been apart of.
Interested in learning more about how TROG contributes to brain and central nervous system cancer results?
See how we contribute to a greater understanding of effective treatments for breast cancer patients.
Understand how TROG contributes to gastrointestinal cancer research and their global results here.
View the successful TROG trial results and outcomes of all gynaecological cancer trials here.
Eager to more about how TROG contributes to head and neck cancer treatments? Click here.
Discover our research within lung cancer and the treatments and trials our team have been apart of.
See how we contribute to a broader understanding of effective treatments for lymphoma cancer patients.
Explore our current oesophageal cancer trials and the impact of TROG.
View the successful TROG trial results and outcomes of all pancreatic cancer trials here.
Understand the degree in which TROG contributes to skin cancer research and global results here.
The radiation medicine research team is multidisciplinary, working with TROG Cancer Research members, hospitals, universities, and trial coordinating centres to advance vital cancer research for the community.
Translational research is a key strength of TROG Cancer Research. Initiatives that were once a part of research projects conducted in laboratories and clinics throughout Australasia are now incorporated into standard care in a clinical setting.
This year we will summit Mt Kosciuszko, all in the name of providing better radiation medicine treatments to cancer patients around the world. Our goal is to raise $25,000 and we want you to help us!
Patients who choose to be part of a cancer clinical trial can be assured that patient safety and radiation therapy protocol compliance is stringently monitored under the TROG Cancer Research Radiation Therapy Quality Assurance (RTQA) program.
As new technologies and techniques are incorporated into radiation therapy treatment, RTQA develops robust radiation therapy planning, delivery, and quality assurance guidelines that ensure compliance and trial quality.
We invite you to explore the cancer clinical trials projects and people leading the fight to cure all cancers with one treatment.
Full membership to TROG Cancer Research is open to anyone qualified in their discipline. This includes Radiation Oncologists, Medical Oncologists, Radiation Therapists, Medical Physicists, Statisticians, Data Managers, Nurses, and Surgeons.
Affiliate membership is also available to anyone qualified or training in a radiation therapy-related discipline. For full details, visit our membership page.
The journey to becoming the 200th participant for the TROG 18.01 NINJA Radiation Therapy Trial has been a remarkably quick...
Read moreThe NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing GP worked with our team last year to create the gift...
Read moreFindings from the BIG 3-07/TROG 07.01 DCIS Trial (Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in...
Read more
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292
